secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014477
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials
---------------------------------------------------------------------------

- Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.
- Cash, equivalents and marketable securities $291.8M as of June 30, 2022, expected to fund operations into H2 2024.
- FDA lifted clinical hold on DYNE-251 IND for Phase 1/2 MAD trial in DMD patients amenable to exon 51 skipping; dosing expected mid-2022.
- New Zealand cleared clinical trial application for DYNE-101 Phase 1/2 MAD trial in DM1; patient dosing expected mid-2022.
- Presented preclinical data for DYNE-101 at ASGCT showing robust DMPK RNA knockdown in muscle models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/0000950170-22-014477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/dyn-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer